chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tested positive for COVID; Tested positive for COVID; This is a spontaneous report from a contactable consumer or other non hcp. A adult patient of an unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection), via an unspecified route of ad-ministration on an unspecified date (Batch/Lot number and Expiry date was unknown) as dose number unknown, single for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient did not have Covid prior vaccination. On an unspecified date, the patient tested positive for covid. No treatment was received for event. The patient underwent lab tests and procedures which included COVID test: positive on an unspecified date. The outcome of event was recovered on an unspecified date.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Chills; Severe body ache; Eye pain; Sore armpit; Malaise; Fatigue; Swollen lymph nodes; This is a spontaneous report from a contactable pharmacist, the patient. A 51-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3246) via intramuscular route of administration in the right arm on 15Jan2021 at 13:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN9581) via an intramuscular route of administration in the right arm on 05Feb2021 at 10:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic migraine, Epstein-Barr virus test, irritable bowel syndrome (IBS-C), hyperlipidemia, carpal tunnel syndrome and gluten intolerance (gluten containing food). The patient previously received nitrofurantoin (MACROBID) on an unspecified date for an unknown indication and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccine with in 4 weeks prior to vaccination. Concomitant medications included verapamil hydrochloride (VERAPAMIL), ropinirole (MANUFACTURER UNKNOWN), levocetirizine dihydrochloride (XYZAL), rosuvastatin calcium (CRESTOR), erenumab (AIMOVIG), vitamin d (MANUFACTURER UNKNOWN) and linaclotide (LINZESS) and VIRACID; all from unknown date for unknown indication unknown if ongoing. On 20Jan2021 at 08:00 the patient experienced chills, sore armpit, severe body ache, eye pain, malaise, fatigue, swollen lymph nodes  which last over 1month. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as result of events. On 23Feb2021, the patient underwent lab test included SAR-CoV-2 test and the result was Ab combo of 0.09. The clinical outcome of the events chills, sore armpit, severe body ache, eye pain, malaise, fatigue, swollen lymph node and sore armpit was recovered with sequelae on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
3/14/22Numbness/tingling LE bilaterally with severe muscle spasms at times.  Feeling off balance at times. 3/17 /22 as above with lip and facial numbness/tingling bilaterally.  3/21/22 as above with numbness/tingling fingertips and thumb bilaterally.
ITP: petechial rash all over body, including over site of vaccine administration; blood clot in mouth, epistaxis, platelet count of 1100, events started 18 hours after administration of influenza vaccine (fluarix); symptoms improved with administration of steroids and IVIG in hospital, patient was discharged 6 days after admission with increased platelet count to 70,000 after treatment and had no further bleeding/petechiae after administration to hospital and treatment.  1/9/07 Received medical records from hospital which reveal patient admitted 10/31/06-11/6/06 with bleeding.  Had red bumps on legs, arms, trunk & back for 2 days prior to admit after received flu shot on day bumps began.  Also had a bloody nose & saw PCP who obtained labs which revealed plts of 1100 & patient sent for admit.  Exam in ER revealed positive blood clot in left buccal mucosa, positive petechiae in upper palate, under tongue, bilateral extremities & back.  Slight tender cervical LAD.  Received steroids & IVIG in ER after heme consult.  Slowly improved & d/c to home on tapering steroids & heme clinic follow up.  FINAL DX: Idiopathic thrombocytopenia.
COVID breakthrough case. I received my 2nd booster shot on 04/19/2022 and my COVID symptoms started on  05/28/2022 around 1-2PM I had a scratchy throat and by the evening I had a low grade fever, headache, tired, fatigue, I  didn't feel like doing anything, exhausted, I felt like I wanted to go sleep. 05/29/2022 I developed cough. I did a COVID home test on 05/29/2022 which was positive. I did a telehealth on 05/30/2022 with a nurse from the health clinic. She  contacted my doctor to get an ok from her about giving medications. She then prescribed me PAXLOVID for 5 days but since it was a holiday it did not arrived till this morning 06/01/2022 but since I am felling better I decided not to take it. I am recovering without medication.
Symptoms did not begin until approx. 10 hours post-injection. Symptoms include redness and swelling at injection site, fever, severe chills, headache, stiffness of neck muscles, and shooting aches/pains through hips.
Vaccine taken Aug 21, 2021. Around Middle of September, I started loosing weight unexplainably, feeling more thirsty than usually, having dry mouth and frequent urination. In December i was scheduled for a medical exam for renewal of my flight medical certificate. Exam showed high levels of sugar in my urine. above 200. Retested next morning while fasting overnight, sugar levels in urine were even higher the next morning. Scheduled to see a primary care. Blood tests were ordered to evaluate my condition. Test reveled low levels of insulin produced by Pancreas due to autoimmune condition. Was diagnosed with Type 1 diabetes. Was refer to Endocrinologist for management and treatment plan.
Pfizer 12/23/20, 1/13/21, 12/17/21, 8/3/22. Positive on 1/3/23
1/6/2021  vaccination; Later that afternoon, I started to go into a 'fog', tired, HA. I could function but nothing seemed 'clear' or 'sharp', 1/7/2021 fatigue, arm sore. The 'fog' was worse; 1/8 fog was really bad; forgetting conversations. 1/9 2:45 in morning. Went to bathroom. Walking, about 1/2 way there, felt like a 'spike' and instant HA. I went to bathroom, door closed, I got sick/vomiting. The shiver, shakes, and fever spiked. I bent down to throw up and I cant relieve. I fell into the wall, pushed self to stand up. Was back in bedroom, laying on floor and passed out. Wife woke me, I was bleeding. Don't know how long I was on the floor. BP144/78, 133 blood sugar, O2 was 98%, temp 98.1. 3:45 I decided to go to hospital, EKG, CT scan, Xray, etc. 'Just fainted'  *PCP stated it was due to shot / vaccine. **busted lip, ER bill ***2nd vaccine; minor side affects (slight HA, )
Expired vaccine was given. Patient will be contacted to repeat dose per CDC guideline/recommendation. This was patient's first dose.
Pt reported that within 2 hours of receiving seasonal flu vaccine both he and wife developed sore throat, then fever and aching with headache and chills. Treated by PCP with Z PACK and resolved after about 10 days.
The patient received a dose of the vaccine following temperature excursions on unknown dates; No adverse event; This spontaneous report as received from a medical assistant refers to a current 5-month-old patient of unknown gender.  The patient's concurrent conditions, medical history and concomitant medications were not provided.   On an unknown date, the rotavirus vaccine, live, oral, pentavalent (ROTATEQ)  (lot # S013439 with expiration date 03-MAR-2021, lot # S013436 with expiration date 30-JAN-2021, and lot # S006050 with expiration date 12-DEC-2020) underwent a temperature excursion.   Temperature Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) Time frame 7 hours 30 minutes Previous temperature excursion? yes, Total Time and LOWEST Temperature BELOW 36°F/2°C (0C) for 8 hours 30 minutes Was call because of a "data logger"? yes  On an unknown date, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) at a dose of 2 ml (route not provided) as prophylaxis. No adverse events were reported.  This is one of several reports received from the same reporter  This spontaneous report as received from a other health professional refers to a patient of unknown age.    On an unknown date the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) lot # S006050, 2 milliliter for prophylaxis.       On an unknown date the patient experienced product storage error and no adverse event.    The outcome of product storage error and no adverse event is unknown.   The reporter considered product storage error and no adverse event to be not assessed to Rotavirus Vaccine, Live, Oral, Pentavalent(ROTATEQ).     {Additional information has been requested. / Additional information is not expected.}; Sender's Comments:  US-009507513-2005USA003382: US-009507513-2005USA004545: US-009507513-2005USA004950: US-009507513-2005USA004951: US-009507513-2005USA004952: US-009507513-2005USA004953: US-009507513-2005USA004954: US-009507513-2005USA004955: US-009507513-2005USA004956: US-009507513-2005USA004957: US-009507513-2005USA004958: US-009507513-2005USA004959: US-009507513-2005USA004960: US-009507513-2005USA004961: US-009507513-2005USA004962: US-009507513-2005USA004963: US-009507513-2005USA004964: US-009507513-2005USA004965: US-009507513-2005USA004966: US-009507513-2005USA004967: US-009507513-2005USA004968: US-009507513-2005USA004969: US-009507513-2005USA004970: US-009507513-2005USA004971: US-009507513-2005USA004972: US-009507513-2005USA004974: US-009507513-2005USA004975: US-009507513-2005USA004976: US-009507513-2005USA004977: US-009507513-2005USA004978: US-009507513-2005USA004979: US-009507513-2005USA004980: US-009507513-2005USA004981: US-009507513-2005USA004982: US-009507513-2005USA004983: US-009507513-2005USA004984: US-009507513-2005USA004985: US-009507513-2005USA004986: US-009507513-2005USA004987: US-009507513-2005USA004988: US-009507513-2005USA004989: US-009507513-2005USA004990: US-009507513-2005USA004991: US-009507513-2005USA004992: US-009507513-2005USA004993:
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history or concurrent conditions was provided. On an unknown date, the patients were vaccinated with doses of GARDASIL (lot # K009482, expiry date 06-MAR-2017 and lot # K011325, expiry date 08-APR-2017; strength, dose, frequency, route of administration were not reported), which were exposed to temperature outside of the recommended range. There were no concomitant therapies reported. No adverse effects were reported. Follow up information has been received on 15-JUL-2015. Patient's demographics has been updated. The patient was vaccinated on 25-JUN-2015. This is one of the several reports received from the same reporter. Additional information has been requested.
a 56 year-old patient received the Arexvy; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 56-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On 01-NOV-2023, the patient received Arexvy (intramuscular). On 01-NOV-2023, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: a 56 year-old patient received the Arexvy). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 03-NOV-2023 A pharmacist called to ask for information regarding the use of Arexvy in patients younger than 60 years of age.  The reporter reported that patient received the Arexvy vaccine and wanted to know if there was safety information concerning this situation. The reporter did not provide patient's initials nor information about the dose given (lot number, expiry date). The reporter consented to follow up. The patient received a dose of Arexvy at an inappropriate age, which led to inappropriate age at vaccine administration.
Administer expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine) in a 27-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medicines were reported.  No treatment medicines were reported.  The vaccine was stored in the freezer and one to two vials were taken out and placed in the fridge each day as needed.
When I was giving him another immunization on 3/2/21, he mentioned that needed to do it in the left arm due to when I gave him second shot of shingrix it formed a hematoma on his right arm, and he showed it to me. H e said that he had been to his dr. His dr said that he could remove it, but the patient declined.
This spontaneous report as received from a registered nurse refers to an unspecified number of unspecified patients of unknown age and gender. Patients' pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On unknown dates, patients were vaccinated with improperly stored doses of M-M-R II (lot number L019989 and expiration date 01-JUN-2017, lot number L026553 and expiration date 16-JUL-2017, dose and route of administration were not reported). The temperature and the time frame of the excursion were 12.3 Celsius degrees for 83 hours and 40 minutes and -3.4 Celsius degrees for 105 hours and 50 minutes. There was no previous temperature excursion and it was stated it was a data logger. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Urinary tract infection; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 30Apr2021 (at age of 34-years old) at 08:30 as a single dose for COVID-19 immunisation. Medical history included the patient had known allergies which included occasional rash with shell fish. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination.  Prior to the vaccination, the patient had not been diagnosed with COVID-19. On 15May2021 at 21:30, the patient experienced urinary tract infection. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of urinary tract infection and included treatment with amoxillin. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event urinary tract infection was not recovered at this time of report.  No follow-up attempts are needed. No further information is expected.
COVID-19; Nasopharyngitis; Exposure to SARS-CoV-2; arm was a little sore; This spontaneous case was reported by an other health care professional (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (arm was a little sore), COVID-19 (COVID-19), NASOPHARYNGITIS (Nasopharyngitis) and EXPOSURE TO SARS-COV-2 (Exposure to SARS-CoV-2) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 028L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Jan-2021, the patient experienced PAIN IN EXTREMITY (arm was a little sore). On 01-Feb-2021, the patient experienced COVID-19 (COVID-19) and NASOPHARYNGITIS (Nasopharyngitis). 01-Feb-2021, the patient experienced EXPOSURE TO SARS-COV-2 (Exposure to SARS-CoV-2). At the time of the report, PAIN IN EXTREMITY (arm was a little sore), COVID-19 (COVID-19), NASOPHARYNGITIS (Nasopharyngitis) and EXPOSURE TO SARS-COV-2 (Exposure to SARS-CoV-2) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Feb-2021, SARS-CoV-2 test: positive (Positive) positive. On 04-Feb-2021, SARS-CoV-2 test: positive (Positive) Tested positive for COVID 19 on 03/31/2021 and 04/02/2021.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided.  Treatment information were not provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Follow-up received on 15-Jun-2021 contains updated suspect products with start date and different batch numbers events Nasopharyngitis
Patient reported feeling drips of vaccine on her arm following the injection. Patient reports that there was no blood on the band aid when removed and she was not aware of any bleeding at the time of injection. There was no pain at the time of the injection and she is not experiencing any tenderness following.  There is concern that a portion of the dose did not enter the muscle as intended and the dose was not adequate. The vaccine was administered at a mass clinic by a volunteer.
Cellulitis left thigh, Treated with Keflex X 10 days.
Patient complained of her left arm being red and swollen and in a lot of pain. Pt got vaccines on 11/2 and reactions started around noon on Saturday 11/3. Patient complained of severe headache also and said she was profusely sweating. She stated that initially she was dizzy, nauseated and disoriented. She called the pharmacy for consultation on 11/5. Patient has been using cold packs, and TYLENOL for headache and pain. I advised her to take BENADRYL for the swelling. I have been following up with the patient since yesterday. Today she is feeling better, her head still hurts but not as much. Her arm is still pink. She is still taking BENADRYL and TYLENOL. Patient has had the flu vaccine in the past with no adverse reaction. Her biggest complaint was a severe headache and arm pain and swelling.
Gave patient the AFLURIA vaccine instead of FLUVIRIN.  No adverse events reported.
Last Friday I started feeling a burning sensation on the lateral side of my right breast, the opposite side of my injection site. The next day I had what looked like a mosquito bite on the right side of my back, in the next couple of days it spread along my back all the way to the side of my breast and into my sternum all on the right side of my body. The rash now small blisters are painful and itchy.
DIZZINESS, LIGHT HEADED, FEELING FAINT; CHILLS; INJECTION SITE PAIN AND SORENESS; HEADACHE; MUSCLE ACHES; NAUSEA; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced dizziness, light headed, feeling faint, chills, injection site pain and soreness, headache, muscle aches, and nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the injection site pain and soreness, headache, muscle aches, nausea, chills and dizziness, light headed, feeling faint was not reported. This report was non-serious.
48 hours post second vaccine symptoms included: fever 48 hours up to 7 days post vaccine symptoms included: leg stiffness behind knee including pain and difficulty walking, pain in back between shoulder blades, joint stiffness in hands. 9 days post vaccine saw Rheumatologist who started patient on Prednisone to knock out arthritis flare
The patient developed a large area of erythema with urticaria on the left arm from the elbow, past the shoulder with swelling.
Patient came to hospital for  atrial fibrillation RVR and just recently received her Moderna booster 6 days ago.
Flu-like symptoms which patient expected but also severe leg pain and loss of appetite.  Pt was advised to consult with physician who advised patient seek emergency help if issue persisted which it did not.  Patient's spouse reported symptom onset the morning after the vaccination
This case was reported by a healthcare professional and described the occurrence of rash in a 12-year-old male subject who was vaccinated with HAVRIX, GlaxoSmithKline.  It was assumed that HAVRIX was administered, the reporter was unclear whether the patient received HAVRIX or Hepatitis A vaccine (Merck).  On 9 November 2007 at 11:00, the subject received 1st dose of HAVRIX (.5 ml, unknown).  At an unspecified time after vaccination with HAVRIX, the subject experienced a rash.  The healthcare professional was notified on 14 November 2007 that the patient developed a rash.  It was reported that the patient was going to be seen in the clinic for follow-up.  The immunization series was delayed.  At the time of reporting, the outcome of the event was unspecified.  The healthcare professional considered the event was possibly related to vaccination with HAVRIX.
This spontaneous report was received from a nurse referring to an unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions, allergies and concomitant medications were not reported. On an unknown date, the patients were vaccinated with improperly stored doses of VARIVAX (strength, dose, frequency, route of administration, lot number and expiration date were not provided) for prophylaxis. No adverse effects were reported. Administered vaccines experienced a temperature of -4.4 degrees Celsius for undetermined time. There was no previous temperature of excursion. Data logger was involved. This is one of two reports received from the same source. Additional information has been requested. Sender's Comments: US-009507513-1705USA007838.
It started hurting the day she got the vaccine. It has the feeling of "having laid on it for a long time". She can't lay on that arm. When she moves her arm a certain way, it hurts more.
numbness in fingers with contraction. lips and tongue swelling. later on with aphagia. next day with low grade fever
Pain in arm. Took 2 ASA when vaccine administered. I have had pain & swelling in all my joints, with decreased range of motion since I received the vaccine. The pain & swelling move around from joint to joint.  I have never had this problem before.  The symptoms decrease with ibuprofen administration.